We are working with Takeda Pharmaceuticals to develop new microbiome therapeutics for patients with Inflammatory Bowel Disease (IBD), beginning with FIN-524. The collaboration combines Finch’s unique discovery platform with Takeda’s strength in drug development for gastrointestinal diseases to advance a new class of microbial therapy.
Takeda is a global research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda’s deep expertise in gastroenterology and recent success in delivering therapies to IBD patients is an ideal complement to our own expertise in microbiome engineering.
To find out more about this collaboration, please see the announcement.